Redefining the Horizon: Is Cure Possible in HER2+ mBC?

With long-term responders still thriving on HER2-directed therapy, clinicians are asking a question that once felt unthinkable in the metastatic setting.

This clip explores the “tail” of the CLEOPATRA trial, the emerging debate around stopping treatment, and why HER2-positive breast cancer may be the first metastatic subtype where a clinical cure is a realistic conversation.